The Journal of Experimental Medicine
ReproCELL
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 12 November 2001. doi:10.1084/jem.194.10.1433
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 91K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reddy, P.
Right arrow Articles by Ferrara, J. L.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reddy, P.
Right arrow Articles by Ferrara, J. L.M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2001/11/1433/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 10, November 19, 2001 1433-1440

Original Article

Interleukin-18 Regulates Acute Graft-Versus-Host Disease by Enhancing Fas-mediated Donor T Cell Apoptosis

Pavan Reddy1, Takanori Teshima1, Mark Kukuruga1, Rainer Ordemann1, Chen Liu2, Kathy Lowler1 and James L.M. Ferrara1

1 Department of Internal Medicine and Pediatrics, University of Michigan Cancer Center, Ann Arbor, MI 48109
2 Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610

Address correspondence to J.L.M. Ferrara, University of Michigan Cancer Center, 1500 E. Medical Center Dr., Ann Arbor, MI 48109. Phone: 734-615-1340; Fax: 734-647-9271; E-mail: ferrara{at}umich.edu

Interleukin (IL)-18 is a recently discovered cytokine that modulates both T helper type 1 (Th1) and Th2 responses. IL-18 is elevated during acute graft-versus-host disease (GVHD). We investigated the role of IL-18 in this disorder using a well characterized murine bone marrow transplantation (BMT) model (B6 -> B6D2F1). Surprisingly, blockade of IL-18 accelerated acute GVHD-related mortality. In contrast, administration of IL-18 reduced serum tumor necrosis factor (TNF)-{alpha} and lipopolysaccharide (LPS) levels, decreased intestinal histopathology, and resulted in significantly improved survival (75 vs. 15%, P < 0.001). Administration of IL-18 attenuated early donor T cell expansion and was associated with increased Fas expression and greater apoptosis of donor T cells. The administration of IL-18 no longer protected BMT recipients from GVHD when Fas deficient (lpr) mice were used as donors. IL-18 also lost its ability to protect against acute GVHD when interferon (IFN)-{gamma} knockout mice were used as donors. Together, these results demonstrate that IL-18 regulates acute GVHD by inducing enhanced Fas-mediated apoptosis of donor T cells early after BMT, and donor IFN-{gamma} is critical for this protective effect.

Key Words: bone marrow transplantation • Th1/Th2 cytokines • IFN-{gamma} • LPS • TNF-{alpha}


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS